Sunbelt Securities’s INmune Bio INMB Stock Holding History

Sunbelt Securities’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38	Buy	34 +26	+325%	+$37	﹤0.01%	2811
2025 Q4	$12	Buy	+8	New	+$14	﹤0.01%	2757

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sunbelt Securities's INMB Position: Q1 2026 in Review

Sunbelt Securities increased its INmune Bio (INMB) stake by 325% in Q1 2026, buying an estimated $37 and bringing the position to 34 shares worth $38. The position accounts for ﹤0.01% of the portfolio, ranked #2811.

Sunbelt Securities first reported a position in INMB in Q4 2025 and has held it in 2 quarters since. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

Sunbelt Securities held 34 shares of INmune Bio worth $38 as of Q1 2026.
Sunbelt Securities bought 26 INmune Bio shares in Q1 2026, an estimated $37.
INmune Bio made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2811 holding.
Sunbelt Securities first reported a position in INmune Bio in Q4 2025 and has held it in 2 quarters since.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.